SoftBank CEO Masayoshi Son Said he Plans to List Arm in New York after the Nvidia Takeover Collapsed

https://www.cnbc.com/2022/02/09/arm-ipo-softbank-to-list-chip-firm-in-new-york-after-nvidia-deal-fails.html?__source=sharebar|twitter&par=sharebar

byCharles Gross

February 9, 2022

1 minute read

https://www.cnbc.com/2022/02/09/arm-ipo-softbank-to-list-chip-firm-in-new-york-after-nvidia-deal-fails.html?__source=sharebar|twitter&par=sharebar

Ventyx Biosciences Q3 EPS $(0.59) Misses $(0.44) Estimate

By Michael Horton

Today, 6:00 AM

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 81.39 percent increase over losses of $(3.17) per share

VTYX

RBC Capital Maintains Outperform on Dollarama, Raises Price Target to C$81

By Benzinga Newsdesk

Today, 6:00 AM

RBC Capital analyst Irene Nattel maintains Dollarama (TSX:DOL) with a Outperform and raises the price target from C$79 to C$81.

TSX:DOL

Provident Financial Hldgs Q2 EPS $0.30 Beats $0.22 Estimate

By Bill Haddad

Today, 6:00 AM

Provident Financial Hldgs (NASDAQ:PROV) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. This is a 87.5 percent increase over earnings of $0.16 per share

PROV

CVS Health Q1 Adj. EPS $2.22 Beats $2.15 Estimate, Sales $76.83B Beat $75.39B Estimate

By Benzinga Newsdesk

Today, 6:00 AM

CVS Health (NYSE:CVS) reported quarterly earnings of $2.22 per share which beat the analyst consensus estimate of $2.15 by 3.26 percent. This is a 8.82 percent increase over earnings of $2.04 per share from the same

CVS

SoftBank CEO Masayoshi Son Said he Plans to List Arm in New York after the Nvidia Takeover Collapsed

Related Posts

Ventyx Biosciences Q3 EPS $(0.59) Misses $(0.44) Estimate

RBC Capital Maintains Outperform on Dollarama, Raises Price Target to C$81

Provident Financial Hldgs Q2 EPS $0.30 Beats $0.22 Estimate

CVS Health Q1 Adj. EPS $2.22 Beats $2.15 Estimate, Sales $76.83B Beat $75.39B Estimate